Global phase 2 data in TNBC look similar to earlier results in China.
ApexOnco Front Page
Recent articles
Giredestrant’s adjuvant benefit looks similar to that of Kisqali and Verzenio.
Readout of the Preserve-003 trial in post-PD-(L)1 NSCLC is due in December.
ASH and SABCS approach.
New first-in-human trials include Kivu and Menarini projects acting on PKT7 and KIF18A.
The project has priority review, but deaths could raise eyebrows.
An in vivo Car-T produced a 100% response rate – in three patients.
Data will be presented on Kura’s Komzifti and Syndax’s Revuforj in first-line AML.
